Biomarkers of phthalates and inflammation: Findings from a subgroup of Women's Health Initiative participants.


Journal

International journal of hygiene and environmental health
ISSN: 1618-131X
Titre abrégé: Int J Hyg Environ Health
Pays: Germany
ID NLM: 100898843

Informations de publication

Date de publication:
05 2021
Historique:
received: 03 11 2020
revised: 08 03 2021
accepted: 15 03 2021
pubmed: 5 4 2021
medline: 26 10 2021
entrez: 4 4 2021
Statut: ppublish

Résumé

Recent experimental work has shown that phthalates may increase inflammation. Prior research has not examined the role of exposure to phthalates in relation to inflammatory status among postmenopausal women who are at higher risk of developing inflammation-related chronic disorders. We aimed to examine the associations of urinary phthalate biomarker concentrations with circulating levels of c-reactive protein [CRP] and interleukin-6 [IL-6] among 443 postmenopausal women selected into a breast cancer case-control study nested within the Women's Health Initiative (WHI). A total of 13 phthalate metabolites were measured in urine samples provided at WHI enrollment from 1993 to 1998. We also measured baseline levels of CRP and IL-6 in these women's serum or plasma samples. Multivariable linear models were used to investigate the role of each phthalate biomarker in relation to CRP and IL-6, adjusting for potential confounding factors and specifically evaluating the role of BMI. In adjusted models we observed positive associations of monocarboxynonyl phthalate (MCNP) with CRP (β = 0.092; 95% CI 0.026, 0.158) and IL-6 (β = 0.108; 95% CI 0.013, 0.204). These positive associations were attenuated and non-significant, however, after further adjustment for body mass index (BMI). In contrast, we observed inverse associations of monoethyl phthalate (MEP) (β = -0.019; 95% CI -0.036, -0.001) and monobenzyl phthalate (MBzP) (β = -0.034; 95% CI -0.058, -0.010) with CRP levels only after adjustment for BMI. Other phthalate biomarkers examined were not significantly associated with either CRP or IL-6 levels. Overall, these results do not suggest an important role for phthalates in promoting an inflammatory response. Future prospective studies are warranted to improve understanding of these associations, particularly in clarifying the role of BMI.

Sections du résumé

BACKGROUND
Recent experimental work has shown that phthalates may increase inflammation. Prior research has not examined the role of exposure to phthalates in relation to inflammatory status among postmenopausal women who are at higher risk of developing inflammation-related chronic disorders.
OBJECTIVES
We aimed to examine the associations of urinary phthalate biomarker concentrations with circulating levels of c-reactive protein [CRP] and interleukin-6 [IL-6] among 443 postmenopausal women selected into a breast cancer case-control study nested within the Women's Health Initiative (WHI).
METHODS
A total of 13 phthalate metabolites were measured in urine samples provided at WHI enrollment from 1993 to 1998. We also measured baseline levels of CRP and IL-6 in these women's serum or plasma samples. Multivariable linear models were used to investigate the role of each phthalate biomarker in relation to CRP and IL-6, adjusting for potential confounding factors and specifically evaluating the role of BMI.
RESULTS
In adjusted models we observed positive associations of monocarboxynonyl phthalate (MCNP) with CRP (β = 0.092; 95% CI 0.026, 0.158) and IL-6 (β = 0.108; 95% CI 0.013, 0.204). These positive associations were attenuated and non-significant, however, after further adjustment for body mass index (BMI). In contrast, we observed inverse associations of monoethyl phthalate (MEP) (β = -0.019; 95% CI -0.036, -0.001) and monobenzyl phthalate (MBzP) (β = -0.034; 95% CI -0.058, -0.010) with CRP levels only after adjustment for BMI. Other phthalate biomarkers examined were not significantly associated with either CRP or IL-6 levels.
CONCLUSIONS
Overall, these results do not suggest an important role for phthalates in promoting an inflammatory response. Future prospective studies are warranted to improve understanding of these associations, particularly in clarifying the role of BMI.

Identifiants

pubmed: 33813346
pii: S1438-4639(21)00058-4
doi: 10.1016/j.ijheh.2021.113743
pmc: PMC8096686
mid: NIHMS1688336
pii:
doi:

Substances chimiques

Biomarkers 0
Environmental Pollutants 0
Phthalic Acids 0
phthalic acid 6O7F7IX66E

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

113743

Subventions

Organisme : NHLBI NIH HHS
ID : 75N92020D00002
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00005
Pays : United States
Organisme : CLC NIH HHS
ID : 75N90021D00004
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00001
Pays : United States
Organisme : CLC NIH HHS
ID : 75N90021D00002
Pays : United States
Organisme : NIDA NIH HHS
ID : 75N95021D00001
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00003
Pays : United States
Organisme : NIH HHS
ID : 75N98021D00005
Pays : United States
Organisme : ORFDO NIH HHS
ID : 75N99021D00001
Pays : United States
Organisme : NLM NIH HHS
ID : 75N97021D00003
Pays : United States
Organisme : NICHD NIH HHS
ID : 75N94021D00002
Pays : United States
Organisme : ORFDO NIH HHS
ID : 75N99021D00002
Pays : United States
Organisme : NICHD NIH HHS
ID : 75N94021D00001
Pays : United States
Organisme : NIH HHS
ID : 75N98021D00004
Pays : United States
Organisme : NHLBI NIH HHS
ID : 75N92020D00004
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01 ES024731
Pays : United States
Organisme : NCI NIH HHS
ID : 75N91021D00001
Pays : United States
Organisme : NIH HHS
ID : 75N98021D00002
Pays : United States

Informations de copyright

Copyright © 2021 Elsevier GmbH. All rights reserved.

Références

Environ Res. 2017 Oct;158:366-372
pubmed: 28686951
Ageing Res Rev. 2011 Jul;10(3):319-29
pubmed: 21145432
Oxid Med Cell Longev. 2009 Jul-Aug;2(3):166-71
pubmed: 20592772
Br J Nutr. 2015 Oct 14;114(7):999-1012
pubmed: 26228057
Health Place. 2013 Mar;20:51-61
pubmed: 23376728
JAMA. 2013 Nov 27;310(20):2191-4
pubmed: 24141714
Toxicol In Vitro. 2004 Jun;18(3):265-9
pubmed: 15046772
J Natl Cancer Inst. 2019 Oct 1;111(10):1059-1067
pubmed: 30629220
Immunology. 2003 Apr;108(4):539-47
pubmed: 12667216
Environ Health. 2019 Mar 12;18(1):20
pubmed: 30866962
Environ Sci Pollut Res Int. 2017 Jan;24(1):284-290
pubmed: 27714659
Nat Rev Clin Oncol. 2015 Oct;12(10):584-96
pubmed: 26122183
Environ Int. 2020 Jun;139:105706
pubmed: 32371302
Circulation. 2004 Jun 1;109(21 Suppl 1):II2-10
pubmed: 15173056
Environ Int. 2017 Dec;109:53-63
pubmed: 28938100
Int J Obes (Lond). 2014 Dec;38(12):1532-7
pubmed: 24722546
Circulation. 2012 Aug 21;126(8):928-33
pubmed: 22891048
Ann Epidemiol. 2003 Oct;13(9 Suppl):S18-77
pubmed: 14575939
Toxicol Appl Pharmacol. 2010 Oct 1;248(1):28-37
pubmed: 20655936
Med Hypotheses. 2018 Jul;116:132-135
pubmed: 29857897
Inflamm Res. 2012 Jan;61(1):69-78
pubmed: 22005928
Environ Res. 2019 Feb;169:122-130
pubmed: 30447499
Environ Toxicol Pharmacol. 2019 May;68:109-119
pubmed: 30884453
Environ Int. 2015 Dec;85:27-39
pubmed: 26313703
Environ Health Perspect. 2004 Mar;112(3):331-8
pubmed: 14998749
Toxicol Lett. 2012 Feb 25;209(1):43-50
pubmed: 22143055
Arch Med Sci. 2017 Jun;13(4):851-863
pubmed: 28721154
PLoS One. 2015 Aug 28;10(8):e0135601
pubmed: 26317519
Environ Sci Technol. 2014;48(15):8881-90
pubmed: 24977926
J Occup Health. 2007 May;49(3):172-82
pubmed: 17575397
Int J Environ Res Public Health. 2016 Mar 14;13(3):
pubmed: 26985901
Biomed Environ Sci. 2016 May;29(5):365-73
pubmed: 27353711
Environ Res. 2011 Jul;111(5):718-26
pubmed: 21349512
Environ Sci Technol. 2014 Jun 17;48(12):7018-25
pubmed: 24845688
Ecotoxicol Environ Saf. 2019 Apr 15;170:391-398
pubmed: 30550969

Auteurs

Avery Trim (A)

Department of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, MA, USA.

Susan E Hankinson (SE)

Department of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, MA, USA.

Simin Liu (S)

Center for Global Cardiometabolic Health, Departments of Epidemiology, Medicine and Surgery, Brown University, USA.

Aladdin H Shadyab (AH)

Department of Family Medicine and Public Health; University of California San Diego School of Medicine; La Jolla, CA, USA.

Jaymie Meliker (J)

Program in Public Health, Department of Family, Population, & Preventive Medicine, Stony Brook University, Stony Brook, NY, 11794, USA.

Wei Bao (W)

Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.

Juhua Luo (J)

Department of Epidemiology and Biostatistics, School of Public Health, Indiana University, Bloomington, IN, 47405, USA.

Buyun Liu (B)

Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, IA, 52242, USA.

JoAnn E Manson (JE)

Department of Medicine, Brigham and Women's Hospital, Harvard Medical School and the Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02215, USA.

Lesley Tinker (L)

Division of Public Health Sciences, Department of Cancer Prevention, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.

Carol Bigelow (C)

Department of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, MA, USA.

Katherine W Reeves (KW)

Department of Biostatistics and Epidemiology, University of Massachusetts Amherst, Amherst, MA, USA. Electronic address: kwreeves@umass.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH